---
title: Integrated mRNA Production Process from E. coli to Highly Purified mRNA
description: When plasmid DNA and mRNA are treated as a single production process, purification steps can be optimized, yields improved, and overall production costs reduced.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![New-ATE-Logo2019](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019.png?width=700&name=New-ATE-Logo2019.png)

## Integrated mRNA Production Process from *E. coli* to Highly Purified mRNA

 Please join us for this free, live Ask the Expert webcast.

Just fill out the form below to register.

|  |
| --- |

## Presenters:

******![Speaker-ales strancar-Picture-B-1067x600-Sartorius-crop](https://bpi.bioprocessintl.com/hs-fs/hubfs/Speaker-ales%20strancar-Picture-B-1067x600-Sartorius-crop.jpg?width=150&name=Speaker-ales%20strancar-Picture-B-1067x600-Sartorius-crop.jpg)******

**Aleš Štrancar**

 Managing Director

BIA Separations, a Sartorius Company

 

Aleš Štrancar is the managing director of BIA Separations, a Sartorius Company, and one of the main inventors of the Convective Interaction Media (CIM) next-generation chromatographic support. He is author or co-author of more than 60 scientific papers dealing with separation and purification technologies. He is a co-author of five granted USA patents and their foreign equivalents in the field of biomolecule separations and purification. He also has co-authored several book chapters dealing with novel chromatography technologies for biomolecule separation. He has co-developed several industrial scale purification processes for companies such as Octapharma (e.g., FIX purification of human plasma protein), Boehringer Ingelheim (plasmid DNA), and Krka of Novo mesto, Slovenia.

## About this event:

#### Date: February 18, 2021

#### Time: 11 am EST | 8 am PST | 5 pm CET

#### Duration: 15 minutes

 

![Sartorius-Logo-RGB-Positiv-72dpi](https://bpi.bioprocessintl.com/hs-fs/hubfs/Sartorius-Logo-RGB-Positiv-72dpi.png?width=262&name=Sartorius-Logo-RGB-Positiv-72dpi.png)

*In vitro* transcription (IVT), the enzymatic process used for the production of mRNA vaccines, differentiates itself from biological fermentation processes by the need for linearized plasmid DNA. The linear isoform is produced with restriction enzymes from open-circular and supercoiled plasmid DNA. Employing a traditional pDNA manufacturing process, which removes linear and open-circular isoforms, will reduce production yield. However, when plasmid DNA and mRNA are treated as a single production process, purification steps can be optimized, yields improved, and overall production costs reduced.

Three key takeaways:

- Learn about a new purification approach starting from *E. coli* through to mRNA production, resulting in improved recoveries, extra-low protein impurities, and very efficient dsRNA removal.
- Get insights into how pDNA linearization based on monoliths is leveraged prior to and during polishing in this purification strategy.
- Understand the use of in-process analytics and mRNA purification tools for improved contaminant removal.

-  

-  

©2015 BioProcess International All Rights reserved